Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients trea...
Saved in:
Main Authors: | Mercedes Lopez-Santalla, Marina Inmaculada Garin |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/294509dff2494d93b2dbd15636a9b0cb |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MSC therapy for inflammatory bowel disease
by: Mikhail A. Konoplyannikov, et al.
Published: (2021) -
CLINICAL EFFECTS OF MESENCHYMAL STROMAL CELLS IN LYMPHOMA PATIENTS WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: E. V. Batorov, et al.
Published: (2012) -
Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature
by: Turse EP, et al.
Published: (2018) -
Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
by: Igor G. Bakulin, et al.
Published: (2021) -
Seminars in inflammatory bowel disease
Published: (2001)